is slated to report second-quarter fiscal 2021 results on Nov 2, before market open.
In the last-reported quarter, the company’s earnings per share (EPS) of $1.31 surpassed the Zacks Consensus Estimate by 35.05%. Moreover, its earnings surpassed the consensus estimate in each of the last four quarters. The trailing four-quarter average earnings surprise was 11.42%.
Let’s see how things have shaped up prior to the announcement.
Factors at Play
Just like many other MedTech companies’ July to September monthly performances, STERIS too is expected to have recorded month-wise rebound in sales on gradual lifting of restrictions in many states and regions. Also, this quarter might have experienced better performance related to deferrable procedures with hospitals gradually reopening their non-COVID departments in a full-fledged way and opening up physician offices and clinics.
In this regard, we note that in the last-reported quarter, STERIS’ biggest segment, Healthcare was most impacted by the reduction in deferrable proceduregiven a pull-back of non-COVID procedures. This is expected to have created significant pent-up demand for the company in the fiscal second quarter.
Within Applied Sterilization Technologies (AST), we expect increased demand from the company’s core medical device customers to have pumped up sales. With the pandemic-led change in market behavior, we expect continued growth in AST facilities that process PPE like gowns and gloves and medical devices for the home setting like insulin pumps and blood glucose monitors. A reduction in devices for deferrable procedures however might have offset this growth in the yet-to-be-reported quarter.
Within Life Sciences, amid the pandemic scenario, the company might have registered benefit from pharma customers on growing vaccines and biologics businesses in its second quarter.
However, the company’s time-deferrable procedure-related devices like orthopedic implants are expected to have once again reported poor results, reflecting a year-over-year decline in procedure volume. The company’s outsource reprocessing business might have been impacted by a decline in procedures. The instrument repair business is expected to have been dull too.
The Zacks Consensus Estimate for second-quarter fiscal 2021 revenues is pegged at $705.2 million, suggesting 4.3% fall from the year-ago reported figure.
The Zacks Consensus Estimate for the company’s EPS of 1.24 cents suggests 6.1% decline from the year-ago reported figure.
What Our Model Suggests
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) along with a positive
has a good chance of beating estimates. However, this is not the case here as you can see:
: STERIS has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our
Earnings ESP Filter
: The company currently carries a Zacks Rank #2.
Stocks Worth a Look
Here are a few medical stocks worth considering, as these have the right combination of elements to beat on earnings this reporting cycle.
has an Earnings ESP of +8.14% and it sports a Zacks Rank of 1 at present. You can see
the complete list of today’s Zacks #1 Rank stocks here.
has an Earnings ESP of +0.35% and is a Zacks #2 Ranked stock.
has an Earnings ESP of +6.67% and it currently carries a Zacks Rank of 2.
Zacks’ 2020 Election Stock Report:
In addition to the companies you learned about above, we invite you to learn more about profiting from the upcoming presidential election. Trillions of dollars will shift into new market sectors after the votes are tallied, and investors could see significant gains. This report reveals specific stocks that could soar: 6 if Trump wins, 6 if Biden wins.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report